Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients  by Marco, Maria Paz et al.
Kidney International, Vol. 56 (1999), pp. 1349–1353
HORMONES – CYTOKINES – SIGNALING
Vitamin D receptor genotype influences parathyroid hormone
and calcitriol levels in predialysis patients
MARIA PAZ MARCO, ISABEL MARTI´NEZ, MARIA LUISA AMOEDO, MERCE` BORRA`S,
RAMO´N SARACHO, JAUME ALMIRALL, JOAN FIBLA, and ELVIRA FERNA´NDEZ
Service of Nephrology, Hospital Universitari Arnau de Vilanova, Department of Medicine and the Department of Basic Medical
Sciences, University of Lleida, Lleida; Service of Nephrology, Hospital de Galdakao, Bilbao; and Consorci Hospitalari Parc
Taulı´, Sabadell, Spain
were: (a) mild CRF group, BB 5.3 pmol/liter (CI 0 to 13.8),Vitamin D receptor genotype influences PTH and calcitriol
Bb 5.5 pmol/liter (CI 2 to 9), bb 5.4 pmol/liter (CI 0.6 to 10.2);levels in predialysis patients.
(b) moderate CRF group, BB 6.2 pmol/liter (CI 1.5 to 10.9),Background. BsmI vitamin D receptor (VDR) gene poly-
Bb 7.8 pmol/liter (CI 5.3 to 10.3), bb 7.5 pmol/liter (CI 4.8 tomorphism has been associated with the severity of hyperpara-
10.1); (c) severe CRF group, BB 9.3 pmol/liter (CI 4.2 to 14.3),thyroidism in patients on hemodialysis. The aim of this study
was to analyze the influence of this polymorphism on parathy- Bb 17.1 pmol/liter (CI 13.9 to 20.2), bb 21.9 pmol/liter (CI 18.7
roid function and serum calcitriol levels in patients with differ- to 25.2). The marginal means of calcitriol adjusted with the
ent degrees of chronic renal failure (CRF) before dialysis. general factorial analysis of variance across the three groups
Methods. A total of 248 CRF patients, divided into three were: (a) mild CRF group, BB 47 pg/ml (CI 37 to 57), Bb 40.9
groups according to creatinine clearance (CCr; mild CRF group pg/ml (CI 37 to 44.8), bb 32.6 pg/ml (CI 26.8 to 38.4); (b)
.60 to #85 ml/min, N 5 54; moderate CRF group .35 to #60 moderate CRF group, BB 24.1 pg/ml (CI 18.3 to 29.8), Bb 26.6
ml/min, N 5 113; severe CRF group .10 to #35 ml/min, N 5 pg/ml (CI 23.5 to 29.7), bb 25.3 pg/ml (CI 22 to 28.6); (c) severe
81), had their serum intact parathyroid hormone (iPTH) and CRF group, BB 27.4 pg/ml (CI 21.3 to 33.5), Bb 19.4 pg/ml
calcitriol levels measured and BsmI genotype frequencies esti- (CI 15.5 to 23.2), bb 20.4 pg/ml (CI 16.1 to 24.7).
mated by polymerase chain reaction (PCR) analysis. Diabetics, Conclusion. The progression of hyperparathyroidism is
those on treatment with steroids, vitamin D or derivatives, and slower in predialysis patients with BB genotypes than in the
phosphorus binding agents were excluded. All those with serum other genotypes. Also, calcitriol levels are less reduced in the
calcium levels of ,2.25 mmol/liter or .2.5 mmol/liter and BB genotype, which may act to lessen the severity of secondary
serum phosphorus levels of .1.6 mmol/liter or who needed hyperparathyroidism.
phosphorus binding agents were excluded. The statistical analy-
sis was done with the general factorial analysis of variance
entering first PTH and then calcitriol as the dependent variable;
BsmI polymorphism of the vitamin D receptor genethe genotype (BB, Bb and bb), sex and CCr group were defined
as factors; and covariables included serum calcium, serum phos- has been reported to be associated with various changes
phorus, 1/creatinine versus time slope, PTH when calcitriol in calcium and bone metabolism [1–5], but there have
was the dependent variable, and calcitriol when PTH was the been substantial discrepancies among different reportsdependent variable.
[6, 7]. Torres et al have recently shown that functionallyResults. When serum PTH levels were entered as the depen-
different alleles of the vitamin D receptor gene maydent variable, serum calcium, CCr group, and the interaction
of genotype with the CCr group were found to be significant condition the bone turnover and the degree of recovery
factors (P 5 0.025, P ,0.001 and P 5 0.039, respectively). of bone mass after renal transplantation [8]. Carling and
When serum calcitriol levels were entered as the dependent
colleagues reported a higher incidence of the bb geno-variable, genotype, the interaction of genotype with CCr, the
type in Swedish primary hyperparathyroidism patientsCCr group, and the 1/creatine versus time slope were found to
be significant (P 5 0.027, P 5 0.028, P ,0.001 and P 5 0.044, [9]. In patients with chronic renal failure (CRF), the
respectively). The marginal means of PTH, adjusted with the degree of secondary hyperparathyroidism varies greatly.
general factorial analysis of variance across the three groups This may be explained, at least in part, by genetic differ-
ences. In a previous study, we found an association be-
tween the BB genotype and relative hypoparthyroidismKey words: hyperparathyroidism, secondary hyperparathyroidism,
chronic renal failure, vitamin D receptor gene polymorphism. in patients on chronic hemodialysis, which disappeared
when the time on hemodialysis exceeded five years [10].
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receptor polymorphism on the progression of secondary performed by BsmI digestion and single-strand confor-
mation polymorphism analysis of PCR-amplified prod-hyperparathyroidism may be more evident at earlier
stages of CRF. To test this hypothesis, we studied the ucts [14]. All blood collections were done with the pa-
tients fasting.influence of this polymorphism on parathyroid function
and serum calcitriol levels in patients with CRF who Genotypes of samples from 220 healthy individuals
from the same geographic areas (control population)were grouped according to the severity of their chronic
renal failure. were also analyzed.
Values are expressed as mean with the 95% confidence
interval (CI). The goodness-of-fit to the Hardy–Wein-
METHODS
berg equilibrium was calculated by the chi-square test.
The study population consisted of 248 nonconsecutive A P value of less than 0.05 was considered statistically
patients (107 males/141 females) with CRF and serum significant. Data in the three groups of patients were
creatinine clearance (CCr) between 10 and 85 ml/min, compared with the general factorial analysis of variance
who were recruited from two neighboring geographic (ANOVA), entering as the dependent variables either
areas in Northern Spain (Bilbao and Lleida). CCr was PTH or calcitriol levels, genotype (BB, Bb, bb), CCr
calculated from plasma creatinine levels by using the group (mild, moderate, severe) and sex as factors, and
Cockcroft formula [13]. Patients with all degrees of pro- as confounding variables: age, serum calcium, serum
teinuria were included. As this was designed as a trans- phosphorus, slope of the 1/creatinine versus time, serum
versal study, the duration of CRF was assessed from the PTH when serum calcitriol was entered as the dependent
distribution of the etiologies of CRF in each group of variable, and serum calcitriol when serum PTH was en-
patients and estimated by using the 1/creatinine versus tered as the dependent variable.
time slope. Two creatinine values where used to calculate
the slope: (1) creatinine levels when the patient was
RESULTSfirst referred to our out-patient clinic, and (2) current
creatinine, determined in the same blood collection as The genotype frequencies estimated for the total pop-
ulation of 248 patients (BB 13.7%, 95% CI 9.6 to 18.2%;the rest of the parameters (serum calcium, serum phos-
phorus, serum PTH and serum calcitriol). Those patients Bb 47.6%, 95% CI 41 to 54%; and bb 38.7%, 95% CI 32.2
to 44.2%) were under the Hardy–Weinberg equilibrium.with a history of diabetes mellitus, or receiving cortico-
steroids, vitamin D or vitamin D derivatives were ex- Genotype frequencies for the three subgroups of patients
according to CCr values were also under the Hardy–Wein-cluded. Patients in this study were on a low-phosphate
diet to control their phosphorus levels, and all those with berg equilibrium except for patients in the mild CRF
group. No differences in allelic frequencies were foundserum calcium levels of ,2.25 mmol/liter or .2.5 mmol/
liter and serum phosphorus levels of .1.6 mmol/liter or between the total population and healthy controls (BB
13.4%, CI 7.3 to 19.5; Bb 55.8%, CI 46.9 to 64.4; bb 30.8,who needed phosphorus binding agents were excluded.
The study protocol was approved by the Institutional CI 22.5 to 39.1), nor between groups, nor between each
group compared with the healthy control group.Review Board, and all patients gave the informed con-
sent to participate in the study. Demographic and biochemical parameters within each
group for the three genotypes are shown in Table 1. ThePatients were divided into three groups according to
the severity of their CRF (mild, moderate and severe). distribution of causes of CRF was similar among patients
with different BsmI vitamin D receptor genotypes, andFor that purpose, the total range of CCr (10 to 85 ml/m)
was divided by three, obtaining three patient groups with there were no significant differences in the slope of
1/creatinine versus time slope among genotypes. Theeach group spanning a 25 ml/min range of CCr: the mild
CRF group, CCr . 60 to #85 ml/min (N 5 54); moderate time between the first and the current creatinine ranged
from 1 to 240 months.CRF group, CCr . 35 to #60 ml/min (N 5 113); and
severe CRF group, CCr . 10 to #35 ml/min (N 5 81). To analyze the differences between the means of PTH
and calcitriol levels taking into account other confound-Serum intact PTH (iPTH) concentrations were measured
by a two-site chemiluminometric assay (normal range 1.2 ing variables we used the general factorial ANOVA.
Serum PTH levels were entered as the dependent vari-to 5.6 pmol/liter; intra-assay and interassay coefficients of
variation were 5% and 6%, respectively). Serum levels of able, genotype (BB, Bb, bb), CCr group (mild, moderate
and severe CRF), and sex as factors with age, serumcalcitriol, calcium, phosphorus, creatinine and CCr were
measured simultaneously in each iPTH determination. calcium, serum phosphorus, 1/creatinine versus time
slope, and serum calcitriol levels as covariables. In thisSerum calcitriol levels were determined using a radiore-
ceptor assay (normal range 18 to 78 pg/ml; intra-assay analysis, serum calcium, the CCr group and the interaction
of genotype with CCr group were significant (P 5 0.025,and interassay coefficients of variation were 10% and
14%, respectively). Vitamin D receptor genotyping was P ,0.001 and P 5 0.039, respectively). When serum
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Table 1. Demographic and biochemical parameters and chronic renal failure (CRF) etiology in the three creatinine clearance (CCr) groups
for the three genotypes
CCr ml/min
. 60 # 85 . 35 # 60 . 10 # 35
Characteristic BB Bb bb BB Bb bb BB Bb bb
N 5 33 16 17 51 45 12 34 35
Sex (M/F) 4/1 18/15 12/4 12/5 28/23 20/25 6/6 19/15 20/15
Mean age years 55 60 57.9 59.9 57.3 64.4 59.22 65.5 59.9
(95% CI) (30.4–79.7) (56.3–63.9) (48.6–67.2) (54.9–64.9) (48.9–65.8) (61.2–67.6) (46.8–71.6) (60.3–70.6) (54.9–64.9)
CCr ml/min 62.5 64.7 63 45.3 48.5 46.8 27.1 23.9 23.3
(95% CI) (57.8–67.2) (62.8–66.5) (60.1–66) (41.9–48.7) (46.5–50.5) (44.8–48.9 (22.8–31.5) (21.3–26.5) (20.3–26.3)
Serum Ca
mmol/liter 2.4 2.3 2.3 2.4 2.4 2.3 2.3 2.3 2.3
(95% CI) (2.2–2.5) (2.2–2.4) (2.3–2.4) (2.3–2.4) (2.3–2.4) (2.2–2.4) (2.3–2.4) (2.2–2.4) (2.2–2.4)
Serum P
mmol/liter 0.9 1 1 1.3 1.1 1 1.2 1.2 1.3
(95% CI) (0.8–1) (0.9–1) (0.9–1) (1.2–1.5) (1–1.2) (1–1.1) (1–1.4) (1.2–1.3) (1.2–1.5)
Serum
1,25(OH)2D3
pg/ml 47 40.9 32.6 24.1 26.6 25.3 27.4 19.4 20.4
(95% CI) (37–57) (37–44.8) (26.8–38.4) (18.3–29.8) (23.5–29.7) (22–28.6) (21.3–33.5) (15.5–23.2) (16.1–24.7)
Serum PTH
pmol/liter 5.3 5.5 5.4 6.2 7.8 7.5 9.3 17.1 21.9
(95% CI) (0–13.8) (2–9) (0.6–10.2) (1.5–10.9) (5.3–10.3) (4.8–10.1) (4.2–14.3) (13.9–20.2) (18.7–25.2)
Slope
1/Creatinine vs. 2.1 3.6 20.87 0.13 0.43 21.9 23.4 22.7 24.4
time (31023) (29–1) (2.1–7.1) (20.4–3) (23–3) (22–3) (23–20.08) (27–0.3) (24–20.9) (26–22)
CRF etiology %
VN 20.5 20.9 16.6 37.5 30.8 23.1 33.4 11.8 32.9
GD 17.5 14 22.2 18.8 15.4 28.2 33.3 23.5 25.7
TIN 30 40 27.8 37.5 41 33.3 25 38.2 15.7
PKD 5 4.7 5.6 0 5 7.7 0 11.8 14.3
U 27 20.4 27.8 6.3 4.7 7.7 8.3 14.7 11.4
Abbreviations are: VN, vascular nephropathy; GD, glomerular disease; TIN, tubulointerstitial nephropathy; PKD, polycystic kidney disease; U, undetermined.
Serum parathyroid (PTH) and calcitriol means are adjusted for the covariables and factors considered in the general factorial analysis of variance.
calcitriol levels were entered as the dependent variable DISCUSSION
with the same factors and covariables, except for PTH The present findings demonstrate the influence of
which was entered as covariable as well, genotype, the BsmI vitamin D receptor genotype on the degree of
interaction of genotype with CCr, the CCr group, and the development of secondary hyperparathyroidism and se-
1/creatinine versus time slope were significant (P 5 0.027, rum calcitriol levels in patients with advanced CRF. The
P 5 0.028, P ,0.001 and P 5 0.044, respectively). effect of BsmI vitamin D receptor gene polymorphism
According to this analysis, the marginal means of PTH, on serum iPTH levels was higher in patients with ad-
adjusted with the general factorial analysis of variance, vanced CRF who were not yet on hemodialysis than in
were higher among patients with severe CRF across the our patients on hemodialysis [10]. The greater genetic
three genotypes when compared to the levels in the impact observed before commencement of dialysis may
groups with mild and moderate CRF. However, the dif- be explained by the fact that the influence of other patho-
ferences between the groups with severe and mild CRF genetic factors is less pronounced. Dialysis itself affects
were significant in the patients with the genotypes Bb serum calcium and phosphorus levels, which in turn regu-
and bb and not in those with the BB genotype, showing late iPTH levels. There are fewer possibilities of devel-
more progression of hyperparathyroidism in patients oping autonomous secondary hyperparathyroidism be-
with the bb and Bb genotypes than in the patients with fore dialysis because of the shorter period of time during
the BB genotype (Fig. 1A). The marginal means of which glandular growth factors have been exerting their
calcitriol, adjusted with the general factorial analysis of proliferative effect.
variance, were higher in patients with the BB genotype We did not find an influence of this polymorphism on
than in those with the bb genotype in the groups with PTH or calcitriol levels in patients at earlier stages of
mild and severe CRF. However, in the group with mod- CRF. Perhaps this influence becomes evident only when
erate CRF there no differences among the three geno- the parathyroid cell is under the stress generated by CRF
and the multiple factors that surround it.types (Fig. 1B).
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Fig. 1. Mean (95% CI) serum parathyroid
hormone (PTH; A) and calcitriol (B) levels
in patients with different vitamin D receptor
(VDR) genotypes and mild, moderate and
severe chronic renal failure (CRF). The sig-
nificant interaction between genotype and cre-
atinine clearance (CCr) group leads to a signifi-
cant increment of PTH levels the bb and Bb
genotypes, but not in the BB genotype. In-
versely, calcitriol levels are higher in the BB
genotype than in the other genotypes in the
mild and severe CRF groups. Symbols are: (h)
mild CRF group; (e) moderate CRF group;
(s) severe CRF group.
It is the first time that the influence of this polymor- tor in the three genotypes. Differences of the vitamin D
receptor mRNA in peripheral blood mononuclear cellsphism on calcitriol levels is found. We cannot establish
from normal volunteers with different genotypes haveif the effect on PTH levels is direct or mediated through
not been found [18]. However, Carling has recentlyits influence on calcitriol levels, or if both mechanisms
found lower levels of vitamin D receptor mRNA andact simultaneously. The mechanism by which BsmI vita-
higher levels of PTH mRNA in cells from parathyroidmin D receptor gene polymorphism influences serum
adenomas of 42 patients with sporadic primary hyper-calcitriol levels in patients with CRF remains to be eluci-
parathyroidism and genotype bb [19]. Accordingly, thedated. Takeyama et al have recently demonstrated that
lower levels of vitamin D receptor mRNA found in thethe negative feedback regulation of active vitamin D
patients with the b allele may affect parathyroid function.synthesis is mediated by 1a-hydroxylase through li-
In contrast with these results, the study by Remus et alganded vitamin D receptor [15]. Moreover, the polyA
shows a lower transactivation ability of the bL haplotypepolymorphism of the VDR locus described by Ingles et
(abstract; ibid). Therefore, more evidence is needed toal is in linkage disequilibrium with the BsmI locus with
conclude that BsmI polymorphism of vitamin D receptorbL and BS being the most common haplotypes [16, 17].
is directly responsible for the clinical association foundRecent results found a lower transactivation ability of
in this study. Furthermore, the 1a-hydroxylase locus hasthe L allele of the polyA polymorphism (abstract; Remus
been recently mapped to 12q13.3, which is within theet al, Bone 23:S198, 1999), and this mechanism could
same region of the vitamin D receptor locus (12q13–14)explain why in CRF, where the number of functional cells
[20]. Therefore, BsmI polymorphism might be a markeris decreased, 1a-hydroxylase would be less efficiently
of 1a-hydroxylase rather than of the vitamin D receptorinhibited in patients with the BB genotype than in those
gene itself.with the bb genotype.
In summary, BsmI vitamin D polymorphism influencesThe duration of CRF is another important factor in-
serum iPTH and calcitriol levels in patients with CRF.volved in the progression of secondary hyperparathy-
The calcitriol levels are less reduced in the BB genotype,roidism. Given that it is extremely difficult to establish
which may act to lessen the severity of secondary hyper-the precise moment at which PTH begins to increase,
parathyroidism. This genetic influence opens a new per-the etiology of CRF provides a fairly good estimation
spective on the pathophysiology of secondary hyperpara-of the duration of CRF. It is well known that patients
thyroidism and may have therapeutic implications.with interstitial nephropathy and polycystic kidneys de-
velop more severe secondary hyperparathyroidism,
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